{"id":"NCT01261325","sponsor":"UCB Pharma","briefTitle":"Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (â‰¥16 to 80 Years Old) With Partial Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2010-12-16","resultsPosted":"2016-08-15","lastUpdate":"2022-07-22"},"enrollment":768,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Brivaracetam","otherNames":[]},{"type":"DRUG","name":"Brivaracetam","otherNames":[]},{"type":"DRUG","name":"Antiepileptic drugs with market authorization available per country","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Brivaracetam 100 mg/ day","type":"EXPERIMENTAL"},{"label":"Brivaracetam 200 mg/ day","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.","primaryOutcome":{"measure":"Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration","timeFrame":"12 week Treatment Period","effectByArm":[{"arm":"Brivaracetam 100 mg/Day","deltaMin":22.8,"sd":null},{"arm":"Brivaracetam 200 mg/Day","deltaMin":23.2,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG001","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":207,"countries":["United States","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Estonia","Finland","France","Germany","Hong Kong","Hungary","India","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Poland","Puerto Rico","Russia","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["27265725","27335114","26471380","27589414","27608437","28236727","27988967","28279891","29414542","29908435","32432339","34218211","35582748","36435010","35285519","34155568","33780735","26899665"],"seeAlso":["https://www.briviact.com/briviact-PI.pdf?v=1479491757","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":261},"commonTop":["Somnolence","Dizziness","Headache","Fatigue","Urinary tract infection"]}}